Biomea Fusion (BMEA) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 42.5% versus a loss of 57.8%. Over five years, ONCY leads with a -77.8% price change compared with -92.1% for BMEA. Oncolytics Biotech is the larger company by market cap ($65.3 million vs $62.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | ONCY |
|---|---|---|
| Share price | $0.8689 | $0.4981 |
| Market cap | $62.82M | $65.31M |
| 1-day change | +3.89% | -9.04% |
| YTD return | -29.93% | -42.75% |
| 1-year return | -42.46% | -57.79% |
| 5-year return | -92.09% | -77.76% |
| EPS (TTM) | $-0.29 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-28.76M |
| 52-week high | $2.24 | $1.32 |
| 52-week low | $0.7995 | $0.44 |
| Distance from 52-week high | -61.16% | -62.27% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +705.62% | +733.17% |
| Average volume | 1.93M | 1.09M |
| Shares outstanding | 72.30M | 131.12M |
| Employees | 37 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed ONCY by 15.3 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
BMEA vs ONCY FAQ
Which is bigger, Biomea Fusion or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $65.31M compared with $62.82M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or ONCY?
BMEA returned -42.46% over the past 12 months, compared with -57.79% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.